Biogen (BIIB) PT Lowered to $338 at RBC Capital on Underappreciated Tecfidera IP Risk
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $338.00 (from $364.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
